Axonics v Medtronic: Fed Circ addresses PTAB ‘errors’

In Axonics v Medtronic, the US Court of Appeals for the Federal Circuit held that the Patent Trial and Appeal Board (PTAB) erred by adopting a claim construction first presented in the patent owner’s response after the institution decision, and refusing to consider the petitioner’s reply arguments and evidence under the new claim construction.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Fed Circ sides with Axonics in patent validity battle

8 August 2023 US Court of Appeals highlights procedural rules in patent dispute concerning medical device charging patents | Medtronic now faces further patent validity reviews after Fed Circ rules in favour of rival.

Medtech

Split Fed Cir refutes Medtronic challenge to catheter patents

25 May 2023 Medtronic prior art reference does not qualify, says Federal Circuit | Firm was hoping to invalidate five catheter technology patents.